Summary
This delay is not good for the company, especially since there are already tests in place that are effective to screen for Down's syndrome. These tests now are the standard of care, so the longer it takes for Sequenon to launch it's test the worse, for the company.
Analysis
This news is bad for the company, since there is already, a good test being used to sceen for Down's symdrome that is currently the standard of care.
Alan Patterson, MD consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
